Abstract: Malignant tumors induce humoral immune response in cancer patients, although the incidence of such autoantibody responses against individual tumor-associated antigens (TAA) is rather low. To increase predictive value of TAA-recognizing autoantibodies as potential cancer biomarkers, TAAs should be combined into protein arrays. Here we review recent advances in the application of such arrays and summarize data concerning most promising antigens. We also review the methods of cloning TAA-recognizing autoantibodies, generation of human hybridomas and screening of recombinant human immunoglobulin libraries.
proteomics, genomics and bioinformatics (reviewed in [9] [10] [11] [12] [13] [14] ) and the utility of TAA panels for cancer diagnostics was demonstrated in several studies [5, 6, [15] [16] [17] . For example, Scanlan et a l. designed a panel consisting of 13 antigens previously identified by SEREX (immunoscreening of tumor-or testis-derived expression libraries with sera from cancer patients) including cancer-testis antigens NY-ESO-1, MAGEA3 and SSX2, and tumor suppressor p53 [15] . Each of these antigens showed reactivity exclusively with colon cancer sera but not with sera from healthy donors. Combination of the antigens resulted in increased diagnostic sensitivity from 4-15% for individual antigens to 46% for the whole panel with a specificity of 100%. In another study by Zhang et a l. [6] , 7 TAAs (c-myc, p53, cyclin B1, p62, Koc, Imp1 and survivin) were employed for serological analysis in patients with various types of cancer in a conventional ELISA assay. Consistent with the data obtained for other antigens, frequency of autoantibody response against any particular TAA ranged from 4 to 25%, while a panel (mini-array) of all seven antigens provided values in the range of 44-68%. However, such combination of antigens resulted in a decreased specificity (down to about 90%) in comparison with specificity of individual antigens (98-99%), but such decrease appeared as a quite reasonable trade-off for the observed gain in sensitivity. The same group also utilized recursive partitioning statistical algorithm to provide classification trees for the selection of antigen subsets with the best values of diagnostic specificity and sensitivity. They found that only 3 out of 7 antigens were required for discrimination between cancer patients and healthy individuals for each type of cancer studied [18] .
Overall, these studies clearly demonstrated the "additive effect" with respect to TAA arrays, and showed the importance of thorough selection of antigens for inclusion into the panel in order to provide Chi-squared test with Yates' correction.
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HCC -hepatocellular carcinoma, SCC -squamous cell carcinoma, HD -healthy donors.
a reasonable balance between diagnostic specificity, sensitivity and number of antigens in the array. Different numbers of available TAAs specific for various malignant diseases indirectly reflect overall immunogenicity of these particular cancer types. The immunogenicity of tumors depends on many factors including the mode of tumor cell death (necrosis vs. apoptosis) [19, 20] and interaction of the tumors with the immune system (reviewed in [21] [22] [23] For example, in hepatocellular carcinoma, a panel of eight full-length tumor-associated antigens (Imp1, p62, Kos, p53, c-myc, cyclin B1, survivin and p16) provided a sensitivity of about 60%, with a specificity of 87.5% [24] . In breast cancer malignancies, the set of 6 antigens (p53, c-myc, HER2/neu, NY-ESO-1, BRCA2 and MUC1) provided 64% sensitivity for breast cancer and 45% sensitivity for ductal carcinoma in situ with a specificity of 85% [25] . Hopefully, these parameters can be further improved by implementation of novel breast cancer and hepatocellular carcinoma-related antigens recently identified by proteomics [26, 27] and by phage display/biopanning [28] (Tables 1 and 2 ).
The TAA arrays may also be used for discrimination of cancer from non-cancerous disease of the same organ/tissue such as benign hyperplasia, inflammation or precancerous lesion. The best examples for such discriminations were obtained for lung cancer. Leidinger et al . used a panel of 82 putative cancer antigens, preselected by SEREX and combined to mini-arrays in a spot-assay format. The highest reactivity with cancer sera (above 15% for each antigen) was demonstrated by 3 TAAs: ROCK1, PRKCB1 and KIAA0376. These antigens reacted neither with normal, nor with non-tumor lung pathologies (NTLP) sera [29] . The authors applied standard Naïve Bayesian method combined with a subset selection approach for sera classification. Panel of 20 antigens with highest information content allowed discrimination of sera from squamous cell lung carcinoma (SCC) patients and normal donors with a sensitivity of 92.9% and a specificity of 93.1%. To separate SCC and NTLP sera, the subset of 69 antigens was applied with a sensitivity of 75.2% and a specificity of 93.5%. Majority of lung cancers are diagnosed in the stages III or IV of disease when the 5-year survival rate is lower than 15% [30] . In this regard discrimination of low-grade SCC (clinical stages IA and IB) patients and healthy donors by subset of 80 antigens with a sensitivity of 79.0% and a specificity of 99.2% is a promising result for early cancer diagnostics [29] .
The same group later applied this approach for accurate discrimination of gliomas from other intracranial tumors as well as from other brain diseases [31] . The panel of 35 antigens, pre-selected by immunoscreening of cDNA expression libraries from brain tumor-derived cell lines was probed with sera Colorectal cancer-8% (n = 50);
Gastric cancer -12% (n = 50);
HCC -6% (n = 50); HD -0% (n = 102) from patients with astrocytic tumors (gliomas), other intracranial tumors (meningioma, pituitary adenoma, acoustic neurinoma, and metastatic tumors), non-tumor neurological diseases (multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy, headache) and from healthy donors. The authors were able to accurately discriminate between glioma carriers and healthy donors (sensitivity 85.2%, specificity 87.8%), between gliomas and other intracranial tumors (sensitivity 86.4%, specificity 89.5%) and between gliomas and non-tumor brain pathologies (sensitivity 93.2%, specificity 81.7%) ( Table 1 ) [31] .
To distinguish between cancer and non-malignant and/or precancerous disease may be of critical importance in liver pathologies. One of the characteristic features of hepatocellular carcinomas (HCC) is its frequent occurrence in patients with chronic liver diseases such as HBV-or HCVassociated chronic hepatitis or liver cirrhosis. Thus, early prediction of transition of these precancerous diseases into invasive cancer would be of great clinical value as it may suggest a curative resection. The most promising antigen for detection of HCC is RNA-binding protein p62. It was originally discovered by immunoscreening of cDNA expression library with serum of HCC patient and was then shown to trigger autoantibody responses in 21% (20/95) of patients with HCC, but not in healthy donors (0/70) or in patients with non-cancerous liver diseases (0/77) [32] . Recently, the same group evaluated antibody responses against eight-antigen panel (IMP1, p62, Koc, c-MYC, p53, cyclin B1, survivin and p16) in patients with HCC, chronic hepatitis, liver cirrhosis, and healthy donors. This TAA mini-array provided sensitivity of 60% for HCC detection. The highest specificity of this test was observed when HCC sera were compared with sera of normal donors (87.8%) and substantially decreased when HCC sera were compared with sera of patients with chronic hepatitis (80%) and liver cirrhosis (70%) ( Table 1 ) [24] .
Discrimination between prostate cancer and benign prostatic hyperplasia (BPH) provides another example of successful application of TAA arrays. The of panel of 10 antigens (c-myc, p53, Koc, IMP1, survivin, p62, p90, cyclin B1, cyclin D1, cyclin A) allowed to distinguish prostate cancer patients from BPH patients or normal donors with a sensitivity of 92.5% and a specificity of 85.2% [33] . This array can be supplemented with other perspective antigens, such as LEDGF/p75 (induce autoantibodies in 18.4% of patients with prostate cancer and 5.5% of healthy donors, but not in BPH patients [34] ) and protein product encoded by transcript FLJ23438 (reacts with 37% of prostate cancer plasma samples, 8.3% of BPH plasma samples and none of healthy donors' samples) [35] . The above examples demonstrate that TAA arrays may be used for distinction of cancer from non-malignant diseases. Such TAA arrays applications appear to be clinically more relevant than discrimination between cohorts of cancer patients and apparently healthy donors.
CLONING OF HUMAN TUMOR-RECOGNIZING ANTIBODIES AS BIOMARKERS AND POTENTIAL ANTI-CANCER REAGENTS
Cloning of human monoclonal antibodies provided another powerful approach for the analysis of humoral immune responses against cancer. Generation of human hybridomas and screening of recombinant antibody libraries not only allowed to identify novel perspective TAAs, but also provided tumor-recognizing antibodies for potential cancer treatment.
Methods for generation of human hybridomas include the fusion of human B cells with human or mouse myelomas, transformation of human B cells by Epstein-Barr virus (EBV) or combination of EBV transformation with the fusion [36] . The main limitations for the development of hybridomas, producing fully human immunoglobulins (Ig) are: 1) low levels of Ig production when human myeloma cell lines are used as fusion partners [37] , 2) cessation of Ig production due to segregation and loss of human chromosomes from the genome when mouse myelomas are used as fusion partners [38] and 3) low stability and clonability in the case of EBV transformation [36] . These limitations may be overcome by the development of improved partner cell lines. Heteromyeloma (B6B11) was generated by fusion of murine and human myeloma cell lines and was further fused with human lymph node lymphocytes to produce a trioma (MFP-2) [39] . Both of these cell lines can be fused easily with human B-cells from spleen and lymph nodes, while MFP-2 also effectively fuses with lymphocytes from peripheral blood. The hybridomas generated by fusion of MFP-2 with lymph node B cells from a breast cancer patient stably produced significant (in the range 10-50 ug/ml/10 6 cells per 24 hours) amounts of human IgM recognizing cancer tissues and/or cancer cell lines. In that case the carboxy-terminal GAIP interacting protein (GIPC1) was identified as the corresponding molecular target [39] [40] [41] .
Interestingly, the majority of cancer-specific antibodies produced by human hybridomas belong to the IgM class, regardless of the method and of the source of B cells (peripheral blood, tumor-draining lymph nodes or tumor-infiltrating lymphocytes) ( Table  3 ) [36, [42] [43] [44] [45] [46] . A rare human hybridoma producing tumor-specific IgG was described by Yamaguchi et al. [36] in which case a melanoma patient was repeatedly vaccinated with allogeneic (SK-MEL-94) and autologous (SK-MEL-94) melanoma cell lines and developed a strong antibody response (protein A reactivity) against allogeneic cells [36] . It is unclear if the bias towards IgM-producing hybridomas reflects an artefact of the fusion and/or transformation techniques or not, but before the selection against TAAs or tumor cells the antibodies of IgA, IgG and IgM classes were represented with comparable frequencies [47] .
TAA-specific IgM antibodies produced by human hybridomas were encoded by a limited number of genes and did not undergo affinity maturation. They were recognized carbohydrate epitopes on modified tumor-specific cell surface glycoproteins [46] . Rare mutations in variable domains of these cancer-specific IgM resulted in decreased reactivity against TAAs, indicating that such antibodies were evolutionary selected for optimal recognition of conserved epitopes [46] . In humans such antibodies are produced by CD5+ B cells and may be classified as natural IgM [46] . CD5+ B-cells and natural IgM represent part of so called "natural immune memory" [48, 49] , but the data concerning functions of human CD5+ cells remain controversial [50] [51] [52] .
Another method used to analyze the repertoire of cancer-specific antibodies and to identify corresponding TAAs is the screening of recombinant antibody libraries. In contrast to cancer-specific IgM produced by human hybridomas, the majority of TAAspecific antibodies obtained by this technology belong to IgG classes [53] [54] [55] [56] . IgG response to TAAs usually has local character and demonstrates bias toward intracellular proteins, probably as the result of their translocation to the cell surface during apoptosis or due to partial necrosis of tumor cells [57] [58] [59] (Table 3) . The preferred sources of B cells for construction of cancerspecific recombinant human immunoglobulin libraries are tumor-infiltrating lymphocytes (TIL) and tumordraining lymph nodes due to the clonal character of part of the B-cell populations (45-68% and 7% correspondingly) [54] . Such libraries can be constructed in a combinatorial single chain variable fragment (scFv) format and cloned into phage-display vectors for further screening [60, 61] . Koltan et a l. demonstrated, that a combinatorial scFv mini-library, constructed from randomly picked V H and V k clones (832 possible combinations) might contain about 1% of cancer-reactive clones [61] . One of 80 bacterial clones was found to produce soluble scFv able to bind to membrane fraction of breast tumor cells or MDA-MB-231 breast cancer cell line. Breast cancer-related ganglioside GD3 was identified as the corresponding molecular target [61] . Pavony et al. constructed several highly complex scFv libraries containing V H and V L domains and effectively performed selection by panning against tumor antigens CEA, MUC-I and ED-B fibronectin domain and MCF7 breast carcinoma cells [60] .
Another possible format of recombinant antibody libraries is based on the fact that human V H domain alone (named single domain antibody, sdAb) retains antigen-binding properties [62, 63] . Such library was generated by cloning into bacterial expression vector of cDNA derived from lymphocytes isolated from tumordraining lymph nodes of breast cancer patients [64] . Screening of breast tumor lysate with this sdAb library and subsequent LC-MS/MS analysis of binding proteins identified neuroplastin/stromal derived receptor-1 (NPTN/SDR-1) as a novel breast cancer antigen inducing humoral immune response.
Cloned TAA-reactive human antibodies may be an important molecular tool not only for cancer detection and disease monitoring, but also for anticancer treatment. First attempts to use hybridomas as a source of fully human tumor-specific antibodies were made in the early 80s of the last century [65, 66] . Watson et a l. reported the implantation of a subcutaneous culture chamber with hybridoma prepared from tumor-infiltrating autologous B lymphocytes in an attempt to treat a patient with recurrent glioma [67] . Natural IgM antibodies recognising glucose-regulated protein 78 kDa (GRP, member of HSP70 family), modified forms of decay acceleration factor (DAF, also named CD55) and cysteine-rich fibroblast growth factor receptor (CFR-1) emerged as promising anti-cancer agents inducing apoptosis of tumor cells [45, [68] [69] [70] . Recently Kurosava et al . reported comprehensive screening for TAAs via isolation of recombinant human monoclonal antibodies using phage-display system [71] . 22 mAb clones recognizing 10 antigens (EGFR, ALCAM, ICAM-1, EpCAM, HGFR, TfR, ITGA3, EMMPRIN, PTP-LAR, and CD44) demonstrated cytotoxic activity against cancer cell lines, thus providing the proof that the screening of recombinant antibody libraries is a promising approach for TAA identification and generation of novel anticancer reagents.
CONCLUSIONS AND PERSPECTIVES
Humoral immunity to malignant diseases is represented by two independent physiological phenomena: 1) natural IgM response to conservative carbohydrate TAA epitopes expressed on the surface of tumor cells and 2) acquired IgG responses to peptide TAA epitopes that become available to immune system due to the death of tumor cells (summarized in • Biological functions remain obscure [58] . Might enhance antitumor T-cell responses [101] [15, 74, 77] . Both types of TAArecognizing antibodies may be used for cancer diagnostics and monitoring. It was shown that the titers of IgG antibodies against intracellular TAAs decrease after resection of the tumor or after its regression due to noninvasive therapy, but may increase in the case of recurrent disease [78] [79] [80] [81] [82] . In contrast, high titers of natural IgM against cell surface TAAs apparently protect from development of cancer in healthy individuals [83] and correlate with better prognosis in cancer patients [84] [85] [86] [87] .
Recent years witnessed a significant progress in the development of TAA arrays. The overall number of discovered antigens appears to be sufficient to make such arrays applicable for cancer diagnostics, but unification of assay format and sera classification algorithms are still required. Serological tests with TAA arrays represent a non-invasive assay potentially applicable for wide population screening. However, high specificity of a particular assay translates into high positive predictive values only in the case of relatively high prevalence of the disease in target population [88] . In this regard monitored cancer patients and patients with chronic diseases that are prone to malignant transformation will certainly benefit from application of TAA arrays. Individuals with high cancer risk, such as smokers or workers occupationally exposed to vinyl chloride represent another primary target group for application of TAA arrays. High risk subjects should also benefit from the application of such assay because antibodies to some TAAs, including p53 and cyclin B1, appear in sera of these categories of individuals months or even years before manifestation of malignant disease [89] [90] [91] .
